TR201902019T4 - Piridilamino asetik asit bileşiği içeren farmasötik preparasyon. - Google Patents

Piridilamino asetik asit bileşiği içeren farmasötik preparasyon. Download PDF

Info

Publication number
TR201902019T4
TR201902019T4 TR2019/02019T TR201902019T TR201902019T4 TR 201902019 T4 TR201902019 T4 TR 201902019T4 TR 2019/02019 T TR2019/02019 T TR 2019/02019T TR 201902019 T TR201902019 T TR 201902019T TR 201902019 T4 TR201902019 T4 TR 201902019T4
Authority
TR
Turkey
Prior art keywords
glaucoma
pyridin
present
pharmaceutical preparation
intraocular pressure
Prior art date
Application number
TR2019/02019T
Other languages
English (en)
Turkish (tr)
Inventor
Shams Naveed
Kroon Henk-Andre
Kawata Hisashi
Kawabata Noriko
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53520400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201902019(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of TR201902019T4 publication Critical patent/TR201902019T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR2019/02019T 2014-01-10 2015-01-08 Piridilamino asetik asit bileşiği içeren farmasötik preparasyon. TR201902019T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461925882P 2014-01-10 2014-01-10

Publications (1)

Publication Number Publication Date
TR201902019T4 true TR201902019T4 (tr) 2019-03-21

Family

ID=53520400

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/02019T TR201902019T4 (tr) 2014-01-10 2015-01-08 Piridilamino asetik asit bileşiği içeren farmasötik preparasyon.

Country Status (26)

Country Link
US (9) US9415038B2 (enExample)
EP (3) EP3424503B1 (enExample)
JP (7) JP5846338B2 (enExample)
KR (1) KR101824829B1 (enExample)
CN (2) CN108743587B (enExample)
AU (1) AU2015205188B2 (enExample)
BR (1) BR112016015763B8 (enExample)
CA (1) CA2936026C (enExample)
CL (1) CL2016001756A1 (enExample)
DK (1) DK3093018T3 (enExample)
EA (1) EA031734B1 (enExample)
ES (2) ES2711091T3 (enExample)
GE (1) GEP20186917B (enExample)
HK (1) HK1223036A1 (enExample)
HU (1) HUE041653T2 (enExample)
IL (1) IL246447B (enExample)
MX (1) MX370361B (enExample)
MY (1) MY163235A (enExample)
PH (1) PH12016501357B1 (enExample)
PL (1) PL3093018T3 (enExample)
PT (1) PT3093018T (enExample)
SG (1) SG11201605653RA (enExample)
TR (1) TR201902019T4 (enExample)
TW (1) TWI598113B (enExample)
UA (1) UA117506C2 (enExample)
WO (1) WO2015105144A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3888654B1 (en) * 2014-01-10 2023-06-14 Santen Pharmaceutical Co., Ltd. Pyridylaminoacetic acid compound and polyoxyethylene castor oil containing pharmaceutical composition
EP3424503B1 (en) 2014-01-10 2020-09-02 Santen Pharmaceutical Co., Ltd Pharmaceutical preparation including pyridylamino acetic acid compound
MX2016009049A (es) * 2014-01-10 2016-09-09 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico.
MX2017007572A (es) * 2014-12-12 2018-02-09 Kowa Co Composicion acuosa.
HK1249443A1 (en) * 2015-07-01 2018-11-02 Santen Pharmaceutical Co., Ltd Depot preparation containing citric acid ester
JP7032134B2 (ja) * 2015-07-09 2022-03-08 参天製薬株式会社 ピリジルアミノ酢酸化合物を含有する予防及び／又は治療剤
JPWO2018230713A1 (ja) 2017-06-16 2020-04-16 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
WO2018230711A1 (ja) 2017-06-16 2018-12-20 学校法人同志社 ｍＴＯＲインヒビターを含む、眼の症状、障害または疾患を治療または予防するための医薬およびその応用
TWI842679B (zh) * 2017-09-29 2024-05-21 日商參天製藥股份有限公司 含有吡啶基胺乙酸化合物之醫藥
JPWO2019124487A1 (ja) * 2017-12-21 2020-12-10 参天製薬株式会社 オミデネパグの組合せ
TWI842692B (zh) * 2017-12-28 2024-05-21 日商參天製藥股份有限公司 含有吡啶基胺乙酸化合物之醫藥製劑
SI3681500T1 (sl) * 2018-04-24 2022-09-30 Allergan, Inc. Uporaba pilokarpinijevega hidroklorida za zdravljenje presbiopije

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
LT2264009T (lt) 2008-03-12 2019-04-25 Ube Industries, Ltd. Piridilaminoacto rūgšties junginys
PL2415763T3 (pl) * 2009-03-30 2016-05-31 Ube Industries Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
US20120202863A1 (en) * 2011-02-03 2012-08-09 Gerald Horn Compositions and methods for treatment of glaucoma
JP2014019650A (ja) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
JP6193655B2 (ja) * 2012-07-13 2017-09-06 参天製薬株式会社 スルホンアミド化合物の組み合わせ
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
US20140018350A1 (en) 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
EP3888654B1 (en) 2014-01-10 2023-06-14 Santen Pharmaceutical Co., Ltd. Pyridylaminoacetic acid compound and polyoxyethylene castor oil containing pharmaceutical composition
EP3424503B1 (en) 2014-01-10 2020-09-02 Santen Pharmaceutical Co., Ltd Pharmaceutical preparation including pyridylamino acetic acid compound
MX2016009049A (es) * 2014-01-10 2016-09-09 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico.

Also Published As

Publication number Publication date
JPWO2015105144A1 (ja) 2017-03-23
US20250235439A1 (en) 2025-07-24
CA2936026C (en) 2022-04-19
ES2711091T3 (es) 2019-04-30
WO2015105144A1 (ja) 2015-07-16
BR112016015763B8 (pt) 2020-09-15
CN108743587B (zh) 2021-04-30
EP3424503B1 (en) 2020-09-02
BR112016015763B1 (pt) 2020-09-01
TWI598113B (zh) 2017-09-11
EP3750541A1 (en) 2020-12-16
EA201691402A1 (ru) 2016-10-31
JP2022111280A (ja) 2022-07-29
CN108743587A (zh) 2018-11-06
KR20160101030A (ko) 2016-08-24
MX370361B (es) 2019-12-10
JP6491588B2 (ja) 2019-03-27
PH12016501357A1 (en) 2016-08-15
EP3093018B1 (en) 2018-11-28
US20180169079A1 (en) 2018-06-21
EP3093018A4 (en) 2017-09-13
AU2015205188A1 (en) 2016-07-14
CA2936026A1 (en) 2015-07-16
PH12016501357B1 (en) 2020-12-09
SG11201605653RA (en) 2016-08-30
EA031734B1 (ru) 2019-02-28
TW201609186A (zh) 2016-03-16
CN105899209A (zh) 2016-08-24
CL2016001756A1 (es) 2017-05-12
JP2024019479A (ja) 2024-02-09
US10702511B2 (en) 2020-07-07
US20220054466A1 (en) 2022-02-24
US11793798B2 (en) 2023-10-24
JP6785330B2 (ja) 2020-11-18
JP2021006593A (ja) 2021-01-21
US20200289483A1 (en) 2020-09-17
US9943510B2 (en) 2018-04-17
JP7402922B2 (ja) 2023-12-21
US11197849B2 (en) 2021-12-14
JP5846338B2 (ja) 2016-01-20
GEP20186917B (en) 2018-11-12
JP2016027060A (ja) 2016-02-18
US20150196541A1 (en) 2015-07-16
KR101824829B1 (ko) 2018-02-01
JP2019108363A (ja) 2019-07-04
MY163235A (en) 2017-08-30
AU2015205188B2 (en) 2019-11-14
CN105899209B (zh) 2018-09-11
JP7087040B2 (ja) 2022-06-20
US12295946B2 (en) 2025-05-13
PT3093018T (pt) 2019-01-10
NZ721620A (en) 2021-08-27
EP3424503A1 (en) 2019-01-09
UA117506C2 (uk) 2018-08-10
MX2016009063A (es) 2016-09-28
HK1223036A1 (zh) 2017-07-21
US20240000763A1 (en) 2024-01-04
EP3093018A1 (en) 2016-11-16
US20190105310A1 (en) 2019-04-11
IL246447A0 (en) 2016-08-31
DK3093018T3 (en) 2019-02-04
USRE48183E1 (en) 2020-09-01
HUE041653T2 (hu) 2019-05-28
US20160324838A1 (en) 2016-11-10
IL246447B (en) 2020-06-30
US10179127B2 (en) 2019-01-15
US9415038B2 (en) 2016-08-16
PL3093018T3 (pl) 2019-05-31
JP2025142352A (ja) 2025-09-30
ES2834334T3 (es) 2021-06-17
JP7726542B2 (ja) 2025-08-20

Similar Documents

Publication Publication Date Title
US12295946B2 (en) Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
WO2017006985A1 (ja) ピリジルアミノ酢酸化合物を含有する予防及び／又は治療剤
HK1225280B (en) Pharmaceutical preparation including pyridylamino acetic acid compound
HK1225280A1 (en) Pharmaceutical preparation including pyridylamino acetic acid compound